A Phase 4 interventional study of two doses enterovirus 71 vaccine in Enterovirus 71 Vaccine, sponsored by Beijing Chaoyang District Centre for Disease Control and Prevention. Status unknown. Open to participants aged 6 Months to 35 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-20.
Sponsored by Beijing Chaoyang District Centre for Disease Control and Prevention · Phase 4, Interventional, and Prevention
This phase IV clinical study evaluates the safety of enterovirus 71 vaccine in children aged 6-35 months old by the method of both passive and active surveillance.
47 studies on the registry are indexed under Enterovirus Infections; 5 are open to participants now.
This study's planned enrollment of 20,000 is above the median of 150 across 31 interventional studies indexed under Enterovirus Infections.
Browse Enterovirus Infections studies →Beijing Chaoyang District Centre for Disease Control and Prevention is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Two doses of enterovirus 71 vaccine will be given in aged 6-35 months old, 28 days interval.
Biological: two doses enterovirus 71 vaccine
Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
The rate of adverse reactions of enterovirus 71 Vaccine
Adverse reactions associated with vaccine will be observed in subjects after each vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy
Time frame: 28 days
No study locations are listed for this record.
This study is status unknown, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Chaoyang District Centre for Disease Control and Prevention